Table 3.
Characteristics of patients with anterior AMI complicated by CS stratified for IABP use.
| Variables | IABP | p-Value | |
|---|---|---|---|
| NO (n = 58) |
YES (n = 87) |
||
| Age (years; median (Q1–Q3)) | 74 (68–82) | 67 (58–74) | <0.001 |
| Age > 75 years (n, %) | 22 (39.3%) | 21 (24.1%) | 0.054 |
| Body mass index (kg/m2, median (Q1–Q3)) | 24.2 (22.8–26.9) | 24.5 (22.8–28.7) | 0.535 |
| Female sex (%) | 16 (28.6%) | 21 (24.1%) | 0.555 |
| Hypertension (%) | 35 (62.5%) | 44 (51.2%) | 0.184 |
| Type II diabetes mellitus (%) | 7 (12.5%) | 18 (20.9%) | 0.197 |
| Anemia (n, %) | 29 (55.8%) | 32 (37.6%) | 0.038 |
| Previous myocardial infarction (%) | 12 (21.4%) | 13 (14.9%) | 0.319 |
| Peripheral arterial disease (%) | 16 (27.8%) | 12 (14%) | 0.044 |
| Out of hospital cardiac arrest (%) | 19 (34.5%) | 40 (46.5%) | 0.178 |
| Heart rate (bpm; median (Q1–Q3)) | 80 (72–102) | 91 (69–109) | 0.706 |
| Baseline blood sugar (mg/dL; median (Q1–Q3)) | 141 (133–181) | 214 (176–263) | 0.005 |
| Left ventricular ejection fraction (median(Q1–Q3)) | 30 (25–40) | 25 (20–35) | 0.041 |
| Baseline hemoglobin (g/dL; median (Q1–Q3)) | 12.3 (11.4–15.1) | 13.9 (12.4–15.1) | 0.058 |
| Baseline platelets (Mu/L, median (Q1–Q3)) | 232 (206–266) | 246 (203–304) | 0.276 |
| Platelets nadir (Mu/L, median (Q1–Q3)) | 188 (159–228) | 137 (101–200) | <0.001 |
| Baseline white blood cells (n × 103/mcl; median (Q1–Q3)) | 12.49 (9.8–16.4) | 14.6 (11.4–21.3) | 0.013 |
| Hyperglycemia (n, %) | 16 (31.4%) | 42 (52.5%) | 0.018 |
| Creatine kinase peak (mg/dMU/L; median (Q1–Q3)) | 2.83 (1.04–4.34) | 4.06 (2.7–7.1) | 0.001 |
| Baseline eGFR * (mg/mL, median (Q1–Q3)) | 44 (36–74) | 65 (43–88) | 0.087 |
| Systolic blood pressure < 90 mmHg in the cath-lab (n, %) | 3 (5.4%) | 19 (25%) | 0.003 |
| Three-vessel disease (%) | 22 (40%) | 31 (37.3%) | 0.754 |
| Left main involvement (n, %) | 2 (3.7%) | 12 (15.2%) | 0.034 |
| ST resolution (%) | 17 (34.7%) | 32 (50%) | 0.104 |
| CI-AKI 0.5 (%) | 14 (26.4%) | 21 (25%) | 0.853 |
| Post-procedural TIMI flow <3 (%) | 13 (23.6%) | 18 (22%) | 0.817 |
| GP IIbIIIa—inhibitors use (%) | 19 (37.3%) | 43 (52.4%) | 0.088 |
| Days in Coronary Care Unit (days; median (Q1–Q3)) | 7 (4–10) | 6 (4–10) | 0.219 |
| Days in hospital (days; median (Q1–Q3)) | 8 (6–15) | 12 (8–19) | 0.003 |
Legend: eGFR = estimated glomerular filtration rate; CI-AKI = contrast-induced acute kidney injury. * eGFR was estimated using Cockroft–Gault formula.